
Search Clinical Trials
| Sponsor Condition of Interest |
|---|
|
Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
National Cancer Institute (NCI)
Myelodysplastic Syndromes
Background:
Myelodysplastic syndromes (MDS) occur when the cells that make blood cells are abnormal.
There are limited treatment options for MDS. Researchers want to learn more through this
natural history study so they can develop better treatments.
Objective:
To study the natural course of MDS1 expand
Background: Myelodysplastic syndromes (MDS) occur when the cells that make blood cells are abnormal. There are limited treatment options for MDS. Researchers want to learn more through this natural history study so they can develop better treatments. Objective: To study the natural course of MDS and MDS/myeloproliferative neoplasms (MPN) and collect biological samples that can help researchers understand the disease. Eligibility: People with suspected or confirmed MDS or MDS/MPN. Healthy donors are also needed. They can be people who are scheduled to donate bone marrow at NIH for a relative, or they may be providing bone marrow in another study. Design: Participants will be screened with a medical history. Participants will have a physical exam. They will give blood and urine samples. They will discuss their symptoms, medications, and ability to perform their normal activities. They will complete surveys about how they are feeling. Participants will have a bone marrow biopsy. A needle will be inserted through a small cut. Bone marrow will be removed. A small piece of bone may be removed. Participants may have an optional skin biopsy. Participants may give optional saliva and stool samples. They may collect these samples at home and mail them to NIH. Participants may undergo optional apheresis. One or two needles or intravenous (IV) lines will be placed in their arm, neck, or groin veins. Blood will be removed. A machine will separate out the white cells. The rest of the blood will be returned to the participant. Participants will be contacted for follow-up once a year for up to 20 years. Healthy donors will have marrow collected for this study during their scheduled procedure with no follow-up. Type: Observational Start Date: Aug 2022 |
|
Psychological Benefits of a Normalized Camping Experience for Children With Cancer
National Cancer Institute (NCI)
Pediatric Cancer
Background:
- Cancer has an enormous impact on the psychological and social well-being of the
family unit. The life-threatening connotations of cancer single out the ill child
from his peer/family group as one who is different, and often unable to maintain a
normal lifestyle. Phy1 expand
Background: - Cancer has an enormous impact on the psychological and social well-being of the family unit. The life-threatening connotations of cancer single out the ill child from his peer/family group as one who is different, and often unable to maintain a normal lifestyle. Physical sequelae of cancer and its treatment accentuate the differences between these children and their normal peers/siblings. - It is important that children with cancer be prepared to function outside of protected situations and begin to develop skills of separation and independence. For healthy children, some of these latter skills are acquired by a camping experience. Such an experience for the patient with cancer is frequently precluded by their dependence on medical facilities and the physical limitations of their activities. - The goal of this study will be to assess the short and long term benefits of the "normalized" camping experience, provided in conjunction with Special Love, Inc., on the patients and staff. In particular, we will seek to determine whether such a comprehensive experience is capable of influencing the attitudes and life experiences of patients and staff in a positive manner. Objectives: -To evaluate the impact of an enriched normalized camping experience on the quality of life of the pediatric cancer patient. In particular, attempts will be made to measure the manner in which this experience influences the child's sense of well-being and self-esteem as well as his or her relationship with parents, family, and peers. Eligibility: - Children 7-17 years of age who are currently being treated for cancer or are up to 3 years post therapy OR Young adults with cancer (YACers) 18-25 years of age who are acting as counselors at Camp Fantastic - All children/young adults will be selected for camp after careful screening by a multidisciplinary committee consisting of medical and program directors. - At the discretion of the multidisciplinary committee consisting of medical and program directors, special exceptions may be made for children with extenuating circumstances. Design: - Assessment of benefit may include interviews with children and families before, during and following camp. Observational data on the child's performance at camp will be noted. - Medical and nursing personnel will consist of staff from the Pediatric Branch at the NCI, other units within the NIH, and participating institutions. - Special Love members, the Program Director at the 4-H Center camp (site of the camp) and Pediatric Branch staff at the NCI will coordinate the camp program, taking into account the medical needs of each camper. - Every attempt will be made to provide a full agenda of age appropriate activities for the patients. - The length of the camping experience for children with cancer will be for 7 days beginning on a Sunday and extending through the following Saturday morning. Patients will be transported to the camp from the NIH Clinical Center and the Virginia hospitals by bus. Type: Observational Start Date: Feb 1983 |
|
Caregiving Networks Across Disease Context and the Life Course
National Human Genome Research Institute (NHGRI)
Inherited Metabolic Disorders
Undiagnosed Diseases
Batten's Disease
Tay Sachs
Diabetes
Background:
In the U.S., about 53 million informal, unpaid caregivers provide care to a person who is
ill, is disabled, or has age-related loss of function. These caregivers may be adult
children, spouses, parents, or others. The stress of providing long-term care affects
caregivers health and wel1 expand
Background: In the U.S., about 53 million informal, unpaid caregivers provide care to a person who is ill, is disabled, or has age-related loss of function. These caregivers may be adult children, spouses, parents, or others. The stress of providing long-term care affects caregivers health and well-being. Researchers want to learn more about this stress and its effects. Objective: To learn how the caregiving process affects the health and well-being of caregivers over time. Eligibility: Adults aged 18 years and older who are caregivers for a person with a chronic medical condition and who have already given consent to take part in other study activities. Design: Participants will be put in different groups. They will complete some or all of the following tasks over 1 year. They may repeat these tasks once a year for up to 5 years. Participants will fill out 2 online surveys. One will ask about their health and their caregiving experience. The other will ask them to list people in their social network and their care recipient s social network who give them support. Participants will have a 2-part phone interview. It will be audio recorded. In part 1, they will be asked about the people they listed in the survey. In part 2, they will be asked about their caregiving experience and events in the care recipient s life. Participants may fill out a weeklong diary every 3 months. It will ask about their daily social activities, well-being, and stress levels. It will also ask about their thoughts and feelings about caregiving. Participants may give a blood sample each year they are in the study. ... Type: Observational Start Date: Sep 2022 |
|
Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults
National Heart, Lung, and Blood Institute (NHLBI)
Cardiovascular Disease
Background:
Omega-7 fatty acids are found in the oil extracted from certain fish and nuts like
macadamia. Palmitoleic acid is one of the most common omega-7 fatty acids. Many studies
suggest that this oil is good for heart health. Researchers want to find out more about
these potential benefits.1 expand
Background: Omega-7 fatty acids are found in the oil extracted from certain fish and nuts like macadamia. Palmitoleic acid is one of the most common omega-7 fatty acids. Many studies suggest that this oil is good for heart health. Researchers want to find out more about these potential benefits. Objective: To study how oil enriched with palmitoleic acid (Omega-7 oil) affects metabolism. Eligibility: Healthy adults at least 18 years old with no known history of cardiovascular disease. Subjects not allergic to fish oil and fish products Females that are not pregnant and are not planning a pregnancy during the length of the study Design: Participants will be screened with questions about their health, medical history, and medicines they take. Participants will have 4 visits over 24 weeks. The visits may include: - Blood drawn from a vein in the arm by a needle stick. Sometimes participants will have to fast before the blood draw. - Vital signs (blood pressure, heart rate, and temperature) taken - Body mass index measured - Cardio-Ankle Vascular Index test may be performed. The stiffness of the participant s arteries will be measured by reading blood pressure in the arms and legs and monitoring the heart. - Optional stool samples - Pregnancy test - A short review of participants physical activity and diet - A supply of dietary supplements to take between visits. Participants will take 4 gel capsules a day. Participants will keep a food and exercise journal Compensation will be provided to subjects that complete the study Check your eligibility for this study by clicking here: https://www.surveymonkey.com/r/DietaryOmega Type: Interventional Start Date: Jul 2018 |
|
Natural History of Stroke: Cause and Development
National Institute of Neurological Disorders and Stroke (NINDS)
Brain Disease
Ischemic Attack, Transient
Cerebrovascular Accident
Cerebrovascular Disorder
Vascular Diseases
The purpose of this study is to learn more about stroke and obtain information that may
serve as the basis for future investigations. It will 1) establish a registry of patients
with cerebrovascular disease (stroke); 2) characterize the natural history of acute
stroke and transient ischemic attacks1 expand
The purpose of this study is to learn more about stroke and obtain information that may serve as the basis for future investigations. It will 1) establish a registry of patients with cerebrovascular disease (stroke); 2) characterize the natural history of acute stroke and transient ischemic attacks (TIA)-an interruption of blood flow to the brain that causes stroke symptoms for a short period of time); and 3) evaluate the data to generate ideas for future studies. Patients 18 years of age or older with suspected acute stroke or TIA may be eligible for this study. Subjects will be recruited from patients who present with stroke at the emergency department of Suburban Hospital in Bethesda, Maryland. The study will gather data collected from diagnostic and laboratory tests the patient undergoes as part of standard medical care, including findings of medical and neurological examinations and other tests. In addition, studies will be done for research purposes only to gather data about stroke and TIA. These may include the following: - Blood and urine tests not more than 2 tablespoons of blood will be drawn for various tests. - Electrocardiogram (EKG) (heart tracing)-electrodes placed on the chest wall detect the heartbeat and heart rhythm. - Computed tomography (CT) scan of the head-specialized X-rays are used to obtain images of the brain. - Magnetic resonance imaging (MRI) of the brain-a strong magnetic field and radio waves are used to produce images that provide information about the brain tissue and blood vessels. - Transcranial Doppler (TCD)-sound waves are used to image the arteries of the brain and neck. - Echocardiogram-sound waves are used to image the heart and evaluate heart function. Patients may be asked to return to Suburban Hospital for follow-up testing in 1, 3, and/or 12 months, when some of these tests may be repeated to assess changes over time ... Type: Observational Start Date: Jan 2001 |
|
Study of Systemic Lupus Erythematosus
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Systemic Lupus Erythematosus
This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their
relatives to learn more about how the disease develops and changes over time. It will
also study genetic factors that make a person susceptible to SLE.
Patients 3 years of age and older with known or suspected S1 expand
This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE. Patients 3 years of age and older with known or suspected SLE and their relatives may be eligible for this study. Patients will be evaluated with a medical history and physical examination, blood and urine tests. Other procedures may include: 1. Electrocardiogram 2. 24-hour urine collection 3. Imaging studies, such as chest and joint X-rays, magnetic resonance imaging (MRI) scans, bone scans, and bone densitometry. 4. Questionnaire about the degree of disease activity, and survey of risk factors for disease complications. 5. Apheresis-Collection of plasma (fluid portion of blood) or blood cells for analysis. Whole blood is collected through a needle in an arm vein. The blood circulates through a machine that separates it into its components. The required component (plasma or cells) is removed and the rest of the blood is returned to the body through the same needle or through a second needle in the other arm. 6. Skin biopsy-Removal of a small skin sample for microscopic analysis. An area of skin is numbed with an anesthetic and a small circular portion (about 1/4 inch in diameter) is removed, using a sharp cookie cutter-type instrument. 7. Kidney, bone marrow or other organ biopsy-Removal of a small sample of organ tissue. These biopsies are done only if they can provide information useful in better understanding the disease or making treatment decisions. 8. Genetic studies-Collection of a blood sample for gene testing. Patients will be followed at least once a year with a brief history and physical examination and routine blood and urine tests. Some patients may be seen more often. Treatment recommendations will be offered to patients' physicians, and patients who are eligible for other research treatment studies will be invited to enroll. Participating relatives of patients will fill out a brief medical history questionnaire and provide a DNA sample (either a blood sample or tissue swab from the inside of the cheek) for genetic testing. Type: Observational Start Date: Feb 1994 |
|
Natural History of Dysregulation and Aging of the Immune System in People With Trisomy 21 With and1
National Institute of Allergy and Infectious Diseases (NIAID)
Down Syndrome
Background:
Down syndrome is a genetic disorder that can cause heart defects and other problems in
the body. People with Down syndrome are more likely to have infections, autoimmunity, and
blood diseases. Some may need surgery to treat congenital heart problems. During this
surgery, doctors someti1 expand
Background: Down syndrome is a genetic disorder that can cause heart defects and other problems in the body. People with Down syndrome are more likely to have infections, autoimmunity, and blood diseases. Some may need surgery to treat congenital heart problems. During this surgery, doctors sometimes remove part of the thymus. The thymus is an organ that plays a role in immune function. People who have had part of their thymus removed may get sick more often than others do. Objective: This natural history study will gather data about how removing part of the thymus affects the health of people with Down syndrome. Eligibility: People aged 1 year and older with Down syndrome. The study will include both people who have, and those who have not had, surgery to remove part of their thymus. Healthy relatives are also needed. Design: Participants with Down syndrome will have clinic visits at least once a year for 15 years. At each visit they will have a physical exam. They will give blood and stool samples. They will have tests of their heart and lung function. Participants aged 18 years or older may have at least 1 imaging scan: They will lie on a table that slides into a donut-shaped machine. The machine uses X-rays to take pictures of the inside of the body. Participants who have tissue samples collected from their bodies (biopsies) taken during the study may have extra tissue taken for research. Healthy relatives will also have visits once a year for 15 years. They will only have a physical exam and provide blood and stool samples. Type: Observational Start Date: Apr 2026 |
|
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Cancer Institute (NCI)
Sarcoma
Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)
Mesothelioma
Pheochromocytoma/Paraganglioma (PPGL)
Pancreatic Ductal Adenocarcinoma
Background:
Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in
cancer-associated fibroblasts of certain cancer types. [18F]FAPI-74 is a new PET
(positron emission tomography) tracer, a substance that is injected into a person s body
before an imaging scan. Researchers1 expand
Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. [18F]FAPI-74 is a new PET (positron emission tomography) tracer, a substance that is injected into a person s body before an imaging scan. Researchers believe that [18F]FAPI-74 PET imaging may be able to visualize cancer more effectively than the approved tracers. If so, the new tracer would make it easier to find FAP-positive tumors in the body. Objective: To see if [18F]FAPI-74 PET scan is as good or better than other imaging methods for detecting certain cancers. Eligibility: People aged 18 years or older with one of these cancer types: pancreatic ductal adenocarcinoma (PDAC), cholangiocarcinoma, hepatocellular carcinoma (HCC), gastric cancer, bladder cancer, ovarian cancer, pheochromocytoma/paraganglioma (PPGL), small cell lung cancer (SCLC) or extrapulmonary neuroendocrine cancer (EP-NEC), mesothelioma or sarcoma. Participants must be scheduled or intended to receive treatment for cancer. Design: Participants will have 2 baseline scans: an [18F]FAPI-74, and the approved tracer [18F]-FDG. The [18F]FAPI-74 will be infused through a needle inserted into a vein. About 1 hour later, the participant will undergo imaging. Within 1 week, participants will undergo the same scanning procedures with the approved tracer. If the baseline scan with [18F]FAPI-74 shows the tumor(s), scans with this tracer will be repeated when their regular treatment regimen calls for scans again. If the scan with the regular FDG also show tumors, this scan will be repeated within the same week as the repeated [18F]FAPI-74 scan. If [18F]-FAPi PET scan shows no tumor(s), scans will not be repeated. If the participant's cancer progresses within 2 years, scans may be repeated. Follow-up calls will continue for 2 years. Type: Interventional Start Date: Sep 2025 |
|
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Cancer Institute (NCI)
Astrocytoma
Glioma
Recurrent Glioblastoma
Background:
Glioblastoma (GBM) is a cancer of the brain. Current survival rates for people with GBM
are poor; survival ranges from 5.2 months to 39 months. Most tumors come back within
months or years after treatment, and when they do, they are worse: Overall survival drops
to less than 10 months.1 expand
Background: Glioblastoma (GBM) is a cancer of the brain. Current survival rates for people with GBM are poor; survival ranges from 5.2 months to 39 months. Most tumors come back within months or years after treatment, and when they do, they are worse: Overall survival drops to less than 10 months. No standard treatment exists for people whose GBM has returned after radiation therapy. Objective: To find a safe schedule for using radiation to treat GBM tumors that returned after initial radiation treatment. Eligibility: People aged 18 years and older with grade 4 GBM that returned after initial radiation treatment. Design: Participants will be screened. They will have a physical exam with blood tests. A sample of tumor tissue may be collected. Participants will undergo re-irradiation planning: They will wear a plastic mask over their head during imaging scans. These scans will pinpoint the exact location of the tumor. This spot will be the target of the radiation treatments. Participants will undergo radiation treatment 4 times per week. Some people will have this treatment for 3 weeks, some for 2 weeks, and some for 1 week. Blood tests and other exams will be repeated at each visit. Participants will complete questionnaires about their physical and mental health. They will answer these questions before starting radiation treatment; once a week during treatment; and at intervals for up to 3 years after treatment ends. Participants will have follow-up visits 1 month after treatment and then every 2 months for 6 months. Follow-up clinic visits will continue up to 3 years. Follow-ups by phone or email will continue an additional 2 years. Type: Interventional Start Date: Oct 2024 |
|
PT-112 in Subjects With Thymoma and Thymic Carcinoma
National Cancer Institute (NCI)
Thymic Epithelial Tumor
Recurrent Thymoma
Thymic Cancer
Background:
There are no approved drugs to treat recurrent thymoma and thymic carcinoma. New
therapies are needed for people with these cancers. Researchers want to see if the drug
PT-112 can help. PT-112 kills cancer cells. It also helps the body s immune system fight
cancer.
Objective:
To see1 expand
Background: There are no approved drugs to treat recurrent thymoma and thymic carcinoma. New therapies are needed for people with these cancers. Researchers want to see if the drug PT-112 can help. PT-112 kills cancer cells. It also helps the body s immune system fight cancer. Objective: To see if the study drug PT-112 can cause tumors to shrink. Eligibility: People ages 18 and older who have thymoma or thymic cancer and whose disease returned or progressed after treatment with at least one platinum-containing chemotherapy, or who have refused standard treatment. Design: Participants will be screened with: Review of medical history and medications Physical exam Blood and urine tests CT or MRI scans of parts of the body, including the brain Participants will get PT-112 in 28-day cycles, on days 1 and 15 of of the first cycle and on day 1 of each cycle after that. They will get the drug by infusion through a catheter. The catheter is a small plastic tube put into a vein. On days they receive the drug, participants will have physical exams and blood and urine tests. They will have an ECG to test heart function on day 1 of each cycle. Participants will have scans every 8 weeks. Participants may choose to have tumor biopsies on day 1 of cycles 1 and 3. Biopsies may be guided by an ultrasound or CT scan. Participants will continue treatment as long as they can handle the side effects and their disease does not get worse, for up to 8 years. Participants will have follow-up visits 2 weeks and 4 weeks after they stop therapy. Then the study team will check on participants every 3 months until 8 years after the participant joined the study. Type: Interventional Start Date: Apr 2022 |
|
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
National Eye Institute (NEI)
Cone-Rod Degeneration
Rod-Cone Degeneration
Background:
The retina is a thin layer of tissue at the back of the eye. Retinal disease usually
reduces a person s mobility because it affects how he or she moves through familiar and
unfamiliar environments. Researchers want to see if a virtual reality (VR) tool can
provide an easier and more ac1 expand
Background: The retina is a thin layer of tissue at the back of the eye. Retinal disease usually reduces a person s mobility because it affects how he or she moves through familiar and unfamiliar environments. Researchers want to see if a virtual reality (VR) tool can provide an easier and more accurate way to assess mobility. Objective: To learn if researchers can track changes in mobility in people with retinal disease using a new VR tool. Eligibility: People aged 5 and older with retinal disease that affects their vision, and healthy volunteers. Design: Participants will have 2-3 clinic visits. Participants will wear goggles or sit in front of a screen while sitting. Using a game controller, they will navigate through 4 obstacle courses presented in VR. Participants will have a medical history exam. They will answer questions about their family history. They will fill out questionnaires about the vision and mobility issues they have in their daily lives. Participants will have a complete eye exam. They will read letters from a chart. Their eye pressure will be measured. Their pupils may be dilated with eye drops. Pictures of their eye will be taken. Lights will be shined in their eyes. Participants will take a visual field test. For this, they will look into a dome and press a button when they see a light. Participants will have an electroretinogram. For this, they will sit in the dark with their eyes patched. Then their eyes will be numbed with eye drops and they will wear contact lenses while watching flashing lights. Participants will have optical coherence tomography. This is a noninvasive procedure. It produces cross-sectional pictures of the retina.... Type: Interventional Start Date: Jul 2023 |
|
Comparison of the Effects of Oral Hygiene Regimens on Clinical, Immunomodulatory, and Microbial Out1
Kenvue Brands LLC
Microbiome
Cytokines
Plaque
Gingivitis
Gingival Bleeding
This study is a six-week, double-blind, randomized, parallel-group controlled clinical
study. The objective of this study is to evaluate the changes to the oral microbiome,
inflammatory mediators, gingival health indices and to assess oral tolerance after 4
weeks of twice daily use of differing ora1 expand
This study is a six-week, double-blind, randomized, parallel-group controlled clinical study. The objective of this study is to evaluate the changes to the oral microbiome, inflammatory mediators, gingival health indices and to assess oral tolerance after 4 weeks of twice daily use of differing oral hygiene regimens including mouthwash compared to a control group. A follow-up assessment will be completed 2 weeks after cessation of treatments. Type: Interventional Start Date: Feb 2026 |
|
Data Collection Study of Pediatric and Adolescent Gynecology Conditions
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Disorders of Sex Development (DSD)
Pediatric and Adolescent Cancers of the Genital Tract
Reproductive Endocrine Conditions in Puberty
Structural Gynecologic Conditions Including Vulvar and Vaginal Conditions
Background:
Gynecologic conditions are those that are related to the reproductive system. They can be
reproductive gland disorders or reproductive system tumors. They can also be inborn
anomalies of the reproductive tract. Researchers want to gather data over time from a
large group of young peopl1 expand
Background: Gynecologic conditions are those that are related to the reproductive system. They can be reproductive gland disorders or reproductive system tumors. They can also be inborn anomalies of the reproductive tract. Researchers want to gather data over time from a large group of young people with these conditions. Objective: To create a database about child and teenage gynecologic conditions. Eligibility: Participants of any age with known or suspected pediatric and adolescent gynecologic conditions, and their adult family members Design: Participants will be screened with a review of their medical records. Participants may have a medical history and physical exam. Participants will have blood drawn using a needle. The blood will be used for genetic tests. Participants will have saliva collected. They will spit into a small plastic container. Or their spit will be absorbed from their mouth using a small sponge. The saliva will be used for genetic tests. Participants may have samples collected from their vagina. A small cotton swab will be used to gather the samples. This procedure is optional. If participants have a surgery related to their condition, a small tissue sample will be taken. It will be stored for future research. Participants may complete optional surveys. These surveys ask about their physical and emotional health. They can choose not to answer any of the questions. Researchers will collect medical data from participants standard tests. Such tests may include blood and urine tests, X-rays, nuclear medicine scans, and other tests. Data will also be collected from standard treatments they may receive. Type: Observational Start Date: Apr 2021 |
|
Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)
National Institute of Allergy and Infectious Diseases (NIAID)
Idiopathic CD4 Lymphopenia
Background:
People with Idiopathic CD4 lymphopenia (ICL) have lower numbers of a type of white blood
cell called CD4 cells. White blood cells fight against infections. Low levels of CD4
cells may make a person more likely to get sick. There are no approved treatments for
ICL. Researchers think a d1 expand
Background: People with Idiopathic CD4 lymphopenia (ICL) have lower numbers of a type of white blood cell called CD4 cells. White blood cells fight against infections. Low levels of CD4 cells may make a person more likely to get sick. There are no approved treatments for ICL. Researchers think a drug called belimumab may be able to help in specific situations. Objective: To see if belimumab is safe for people with ICL. Eligibility: People ages 18-70 who have ICL and are participating in NIH protocol 09-I-0102 (EPIC) Design: Participants will be screened with: Medical and medication history Physical exam Questionnaire about mental health and depression Blood and urine tests Participants will have a baseline visit. This will include some repeats of the screening tests. They may also have leukapheresis: Blood will be taken from a needle in one arm and passed through a machine that separates out the white blood cells. The rest of the blood will be returned through a needle in the other arm. Participants will receive 8 doses of belimumab through IV: A needle will insert a thin plastic tube into an arm vein. Belimumab will be given through the IV line. The first 3 doses will be given every 2 weeks. The other 5 will be given once every 4 weeks. Participants will have a physical exam and blood and urine tests at each dosing visit. They will be monitored for up to 4 hours after the infusion. Participants will have 3 follow-up visits, at around 8, 16, and 24 weeks after the last dose of belimumab. They will have a physical exam and blood and urine tests. Once they finish this protocol and they will continue to be followed under 09-I-0102 (EPIC study). Type: Interventional Start Date: Jan 2020 |
|
Developing Transcranial Neuromodulation Protocols for Learning and Decision-Making
National Institute on Drug Abuse (NIDA)
Normal Physiology
Background:
People with substance use disorder (SUD) often have changes in brain function that can
make it difficult to control drug-seeking behavior. These changes may heighten the urge
to use drugs or lessen the desire to seek nondrug-related rewards. Researchers want to
know how a technique cal1 expand
Background: People with substance use disorder (SUD) often have changes in brain function that can make it difficult to control drug-seeking behavior. These changes may heighten the urge to use drugs or lessen the desire to seek nondrug-related rewards. Researchers want to know how a technique called transcranial magnetic stimulation (TMS) may cause changes in brain activity that may help people with SUD. Objective: To test TMS in healthy volunteers. Eligibility: Healthy people aged 18 to 45 years who are right-handed. Design: Participants can volunteer for up to 5 different experiments. Each experiment requires 2 to 8 clinic visits. Each visit will last 3 to 7 hours. Some visits will include TMS. A coil will be placed on the participant s head. A brief electrical current will pass through the coil to create a magnetic field. Participants may feel a tapping or pulling sensation on the skin under the coil. They may feel a twitch in their face, neck, arm, or leg muscles. Participants may be asked to tense certain muscles during TMS. Some visits will include functional magnetic resonance imaging (fMRI) scans. Participants will lie on a bed that slides into a large tube. They will perform tasks on a computer inside the tube. The fMRI will show which parts of the brain are used during each task. Participants will perform tasks on a computer. Some tasks may be done at a desk as well as during TMS and fMRI. Participants may look at images, listen to sounds, smell odors, or taste flavored liquids. Their vital signs may be monitored and their eye movements may be tracked during tasks. Type: Interventional Start Date: Apr 2026 |
|
DDAVP for Pituitary Adenoma
National Institute of Neurological Disorders and Stroke (NINDS)
Cushing's Disease
Pituitary Adenoma
This study is designed as a single institution trial. The study utilizes safe and
clinically-validated tools for preoperative workup of patients with small pituitary
tumors. DDAVP stimulation and 18F-labeled fluoro-deoxyglucose (FDG) uptake for
PET-imaging will be used to detect MRI-negative pituit1 expand
This study is designed as a single institution trial. The study utilizes safe and clinically-validated tools for preoperative workup of patients with small pituitary tumors. DDAVP stimulation and 18F-labeled fluoro-deoxyglucose (FDG) uptake for PET-imaging will be used to detect MRI-negative pituitary adenomas in patients with Cushing s disease. Patients who have MRI-negative pituitary microadenomas will undergo FDG PET-imaging with DDAVP stimulation. Intravenous FDG will be given approximately four hours following DDAVP administration. Within 12 weeks after completion of the FDG high-resolution PET scan, patients will undergo surgical resection of the pituitary adenoma. Surgical and histological confirmation of adenoma location will be noted. All images will be read independently by neuroradiologists blinded to clinical and histopathological outcomes. The diagnostic and localization accuracy of PET-imaging will be assessed by comparing the PET findings with histopathology. Type: Interventional Start Date: Mar 2026 |
|
Perception, Sensation, Cognition and Action in Humans
National Eye Institute (NEI)
Normal Physiology
Background:
When people see and hear, the brain changes signals from the eyes and ears into
perceptions and thoughts. No one fully understands how this happens. Researchers want to
explore how healthy brains process sights and sounds.
Objectives:
To explore how people understand what they see an1 expand
Background: When people see and hear, the brain changes signals from the eyes and ears into perceptions and thoughts. No one fully understands how this happens. Researchers want to explore how healthy brains process sights and sounds. Objectives: To explore how people understand what they see and hear when the brain processes sights and sounds. Eligibility: Participants aged 13-65 who have at least 20/40 vision in at least one eye and do not use a hearing aid. Design: Some participants will take tests online anonymously. They will do computer tasks related to colors and behavior. In-person participants will be screened with medical history and physical exam. They will complete questionnaires and vision and hearing tests. Participants will plan how many testing sessions they will have and when. Sessions last 2-5 hours. They may include: - Magnetic Resonance Imaging: Magnets and radio waves to take pictures of the brain. Participants will lie on a table that slides in and out of a tube. They will do a task during the scan. - Magnetoencephalography: Records magnetic field changes from brain activity. Participants will sit or lie down. A cone will be lowered onto their head. They may do a task during the test. - Electromyography: Electrodes attached to the skin will measure the electrical activity of muscles. - Electroencephalogram: Electrodes on the scalp will record brain waves. - Electrocardiography: Electrodes on the chest will record heart electrical activity. - Tests of memory, attention, thinking, vision, and hearing. - Eye Tracking: Cameras will follow participants eye movements. They may wear a cap with infrared cameras in front of their eyes. During the sessions, participants vital signs may be monitored. ... Type: Observational Start Date: Mar 2019 |
|
Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Mult1
National Cancer Institute (NCI)
Glioblastoma Multiforme
This study will collect blood and urine samples from patients undergoing radiation
therapy for glioblastoma multiforme (a type of brain tumor) to investigate the effects of
this treatment on blood cells and certain proteins. The information from this study may
help scientists develop new tests to m1 expand
This study will collect blood and urine samples from patients undergoing radiation therapy for glioblastoma multiforme (a type of brain tumor) to investigate the effects of this treatment on blood cells and certain proteins. The information from this study may help scientists develop new tests to measure radiation exposure and find new ways to treat cancer with radiation, and help determine which kinds of patients or tumors respond better to radiation therapy. Two proteins of particular interest in this study and which may be involved in the recurrence of cancer are VEGF (vascular endothelial growth factor) and MMPs (matrix metalloproteinases). Patients 18 years of age and older with glioblastoma multiforme who are receiving or will receive radiation therapy as part of their medical treatment may be eligible for this study. Candidates are screened with a history and physical examination, blood tests, and magnetic resonance imaging (MRI) of the brain. Participants will have blood and urine samples collected before, during and after completion of their radiation treatment. Urine samples are collected in a cup and about 2 tablespoons of blood are withdrawn through a needle in a vein. Additional samples may be requested at different times during treatment and in the 3-year follow-up period. Type: Observational Start Date: Jun 2004 |
|
Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Obesity
Type 2 Diabetes
Background:
Type 2 diabetes is a disease that affects blood sugar levels. Complications can include
heart and blood vessel (vascular) diseases. Rates of type 2 diabetes have tripled in
children and young adults over the last 40 years. Vascular diseases are also increasing
in young people.
Objecti1 expand
Background: Type 2 diabetes is a disease that affects blood sugar levels. Complications can include heart and blood vessel (vascular) diseases. Rates of type 2 diabetes have tripled in children and young adults over the last 40 years. Vascular diseases are also increasing in young people. Objective: To learn more about factors, including type 2 diabetes, that may cause vascular disease in young people. Eligibility: People aged 12 to 25 years who (1) have type 2 diabetes; (2) are overweight but not diabetic; (3) or are lean and healthy. Biological parents are also needed. Design: Young participants will visit the NIH clinic once a year for up to 25 years. Each visit will take 4 days. Before each visit, participants will wear devices to track their sleep, activity, and blood sugar levels for 7 to 10 days. At each visit, participants will have tests including: Samples: They will provide blood, urine, and stool samples. Heart: They will ride a stationary bike for 6 minutes with stickers applied to their chest. Scans: They will lie on a bed that slides into a tube; the machine will take pictures of the inside of their body. Energy: They will wear a hood over their head to measure the air they breathe. Social stress: They will give a speech for 10 minutes to show their body s response to stress. Glucose: They will drink a sweet drink to see how their blood sugar changes. Biological parents will have 1 study visit. They will have blood tests. They will fill in questionnaires about their lifestyle and stress. ... Type: Observational Start Date: Mar 2025 |
|
Defining the Brain Phenotype of Children With Williams Syndrome
National Institute of Mental Health (NIMH)
Williams Syndrome
Duplication
Background:
- Little is known about how the brain changes during childhood and adolescence, how genes
affect this process, or how the brains of people with 7q11.23 genetic variation change
during this period. Researchers are interested in using magnetic resonance imaging to
study how the brain cha1 expand
Background: - Little is known about how the brain changes during childhood and adolescence, how genes affect this process, or how the brains of people with 7q11.23 genetic variation change during this period. Researchers are interested in using magnetic resonance imaging to study how the brain changes in healthy children and children with 7q11.23 genetic variation, including Williams syndrome and 7q11.23 duplication syndrome. Objectives: - To study developmental changes in the brains of healthy children and children who have been diagnosed with Williams syndrome,7q11.23 duplication syndrome, or other 7q11.23 genetic variation. Eligibility: - Healthy children and adolescents between 5 and 17 years of age. - Children and adolescents between 5 and 17 years of age who have been diagnosed with Williams syndrome, 7q11.23 duplication syndrome, or have other 7q11.23 genetic variation. Design: - Participants will have a brief physical examination and tests of memory, attention, concentration, and thinking. Parents will be asked about their child s personality, behavior characteristics, and social interaction and communication skills. - Both participants and their parents may be asked to complete additional questionnaires or take various tests as required for the study. - Participants will have approximately 10 hours of magnetic resonance imaging (MRI) scanning, usually over 4 to 5 days, within a one month period. Some of these tests will require the participants to do specific tasks while inside the MRI scanner. - Participants will be asked to return to the National Institutes of Health clinical center to repeat these procedures every 2 years thereafter until age 18. Type: Observational Start Date: Jan 2011 |
|
Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy
National Cancer Institute (NCI)
Cancer
BACKGROUND
- This protocol acknowledges that it is in the interest of the NIH and ROB, as well as
our participants, to continue to follow those who have been treated with
radiotherapy at ROB and are not otherwise eligible for current active research
protocols.
- It also provi1 expand
BACKGROUND - This protocol acknowledges that it is in the interest of the NIH and ROB, as well as our participants, to continue to follow those who have been treated with radiotherapy at ROB and are not otherwise eligible for current active research protocols. - It also provides a mechanism for the correlation and interpretation of disparate data for research into the long term side effects and outcomes for a variety of disease entities and treatments, such as combined modality treatment, MoAb, PDT, radiation modifiers, intraoperative radiotherapy, etc. OBJECTIVE -The primary objective of this protocol is to assess the late effects of treatment and the natural history of disease through collection of data from any standard procedures performed as part of follow up care on participants previously treated with radiotherapy. ELIGIBILITY -Participants who received radiation therapy. DESIGN - This is a natural history protocol in which long-term follow up data will be collected from participants who received radiation therapy. - It will be made clear to participants in the consent form, that data collected during their follow-up may be used anonymously for publications concerning the natural history of disease processes and long-term effects of treatment. Type: Observational Start Date: Feb 2000 |
|
Natural History Study of Parathyroid Disorders
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Parathyroid Cancer
Primary Hyperparathyroidism
Pseudohypoparathyroidism
Inheritable Bone Diseases
Multiple Endocrine Neoplasia, Type 1
Background:
Parathyroid disorders are very common in the general population and include disorders of
parathyroid excess, deficiency, or defects in parathyroid hormone (PTH) signaling. PTH,
the main secretory product of parathyroid glands is responsible for regulation of
calcium-phosphate homeostas1 expand
Background: Parathyroid disorders are very common in the general population and include disorders of parathyroid excess, deficiency, or defects in parathyroid hormone (PTH) signaling. PTH, the main secretory product of parathyroid glands is responsible for regulation of calcium-phosphate homeostasis. Objective: i) To investigate the cause of parathyroid disorders ii) To describe evolution, natural history, and longitudinal trends of parathyroid and related disorders seen in syndromic presentations like multiple endocrine neoplasia, hyperparathyroidism-jaw tumor syndrome Eligibility: People ages 6 months older who have, are at risk of having, or are related to a person with a parathyroid or related disorder. Design: Participants will be screened with a review of their medical records. Participants will be seen, tested, and treated by doctors based on their condition. Their visits may be in person or via telehealth. Participants will complete questionnaires. They will answer questions about their physical, mental, and social health. Participants may give samples such as saliva, blood, urine, or stool. Participants may give cheek cell samples. They will do this using a cheek swab or by spitting into a cup. Adult participants may give a skin biopsy. For this, a small bit of skin is removed with a punch tool. Participants may have medical photos taken. If participants have surgery during the course of their regular care either at the NIH or at a different hospital or doctor s office, researchers will ask for some of the leftover tissue. Participants will be in the study as long as they are being seen by their doctor. Type: Observational Start Date: Nov 2021 |
|
Normal Values in Hearing and Balance Testing
National Institute on Deafness and Other Communication Disorders (NIDCD)
Healthy Volunteer
Background:
- Researchers at the National Institutes of Health give many tests of hearing and
balance. These tests can help detect problems that affect hearing or balance. It is
important to know exactly how healthy people perform on each of these tests. This
information will indicate when a test1 expand
Background: - Researchers at the National Institutes of Health give many tests of hearing and balance. These tests can help detect problems that affect hearing or balance. It is important to know exactly how healthy people perform on each of these tests. This information will indicate when a test result is normal and when a test result shows a problem. Researchers also want to determine the best methods for each test. Objectives: - To test different types of hearing and balance tests, and collect information on normal values for each test. Eligibility: - Healthy volunteers between 5 and 80 years of age. Design: - This study will require a single visit to the National Institutes of Health Clinical Center. It will include both screening tests and study tests of hearing and balance. Sometimes, a second visit may be required if a test is designed to measure the same thing on 2 different days. Each visit will last between 2 and 5 hours, depending on the number of tests scheduled per visit. - Participants will have a physical exam and medical history. They will also have basic tests to check for normal hearing and balance. - Participants may have different hearing tests, including the following: - Auditory Evoked Potentials to study how the ears and brain handle sound information. - Auditory Processing Tests to study how a person processes complex sounds like speech in background noise. - Tests of middle ear and inner ear function. - Participants may have different balance and inner ear tests, including the following: - Balance test on a tilting platform. - Different tests to measure how well the eyes, ears, and brain work together to help maintain balance. - Treatment will not be needed as part of this study. Type: Observational Start Date: Sep 2012 |
|
Characterization of Diseases With Salivary Gland Involvement
National Institute of Dental and Craniofacial Research (NIDCR)
Healthy Volunteer
Sjogren's Syndrome
Salivary Gland Disease
Background:
- Salivary glands in and around the mouth and throat make saliva. Salivary gland
disorders can affect a person s quality of life. Studying people who have a disease that
affects their salivary gland(s) may teach researchers about the disorders and their
genetics.
Objectives:
- To stu1 expand
Background: - Salivary glands in and around the mouth and throat make saliva. Salivary gland disorders can affect a person s quality of life. Studying people who have a disease that affects their salivary gland(s) may teach researchers about the disorders and their genetics. Objectives: - To study salivary gland diseases and disorders. To collect data and samples from people with salivary gland problems and their relatives. Eligibility: - People more than 4 years old who have or are suspected to have a disease involving salivary glands. - Their relatives more than 4 years old. - Healthy volunteers 18 years or older. Design: - Participants may be screened with: - Medical history - Physical exam - Blood and urine tests - General oral and dental history and exam - Saliva collection - Eye exam and test for dry eyes - Health questionnaires (adults) - Biopsy of some minor salivary glands. A small incision will be made on the inside of the lower lip and several tiny salivary glands will be removed. - Participants will have 2-3 visits. These may include: - Repeats of some screening tests - Ultrasounds of some glands. Researchers will put some gel on the face, then press on it with a smooth wand. - Adults may have other biopsies - A small catheter inserted into the opening of the parotid gland duct on the inside of the cheek. A saline solution (in a syringe) will fill the duct. - Swishing a saltwater solution in the mouth for 10 seconds and then spitting into a cup - Scrapings collected from teeth, tongue, and cheeks Type: Observational Start Date: Apr 2015 |
|
The Pathogenesis and Natural History of Sjogren's Disease
National Institute of Dental and Craniofacial Research (NIDCR)
Sjogren's Syndrome
Salivary Gland
Pathogenesis
Background:
-Sjogren s Disease (formerly: Sjogrens Syndrome, Sj(SqrRoot)(Delta)gren s syndrome) is a
disease that affects about 1-4 million Americans. It is more common in women. It mainly
affects the glands that produce saliva and tears, leading to dry eyes and dry mouth. The
cause of Sjogren s D1 expand
Background: -Sjogren s Disease (formerly: Sjogrens Syndrome, Sj(SqrRoot)(Delta)gren s syndrome) is a disease that affects about 1-4 million Americans. It is more common in women. It mainly affects the glands that produce saliva and tears, leading to dry eyes and dry mouth. The cause of Sjogren s Disease is unknown, but inflammation plays an important role. The purpose of this study is to learn more about Sjogren s Disease. Objectives: -To better understand how Sjogren s Disease begins and how it affects patients so that we can develop better ways to treat them. Eligibility: - Participants must be 16 years of age or older. - They must have a diagnosis of Sjogren s Disease or have at least two symptoms of Sjogren s Disease. Design: - People taking part in the study will come to the NIH Clinical Center for at least three visits. - During these visits, participants will have a medical history and physical exam. They will have oral and dental assessments, and saliva collection. Lab tests (blood and urine) and dry eye exams will be done. Participants will answer questionnaires and have salivary scintigraphy (adults only unless required for diagnosis). - Other optional tests may also be done. Participants may have to come in for additional visits if they have these optional tests or if their disease changes. - The only treatment provided as part of this study is for medical emergencies or complications that occur while you are at NIH for evaluation. Type: Observational Start Date: Jan 2012 |